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Abstract
Background: Polyamine biosynthetic pathway is a validated therapeutic target for large number of infectious diseases
including cancer, giardiasis and African sleeping sickness, etc. a-Difluoromethylornithine (DFMO), a potent drug used for the
treatment of African sleeping sickness is an irreversible inhibitor of ornithine decarboxylase (ODC), the first rate limiting
enzyme of polyamine biosynthesis. The enzyme ODC of E. histolytica (EhODC) has been reported to exhibit resistance
towards DFMO.
Methodology/Principal Finding: The basis for insensitivity towards DFMO was investigated by structural analysis of EhODC
and conformational modifications at the active site. Here, we report cloning, purification and crystal structure determination
of C-terminal truncated Entamoeba histolytica ornithine decarboxylase (EhODCD15). Structure was determined by molecular
replacement method and refined to 2.8 A˚ resolution. The orthorhombic crystal exhibits P212121 symmetry with unit cell
parameters a= 76.66, b= 119.28, c= 179.28 A˚. Functional as well as evolutionary relations of EhODC with other ODC
homologs were predicted on the basis of sequence analysis, phylogeny and structure.
Conclusions/Significance: We determined the tetrameric crystal structure of EhODCD15, which exists as a dimer in solution.
Insensitivity towards DFMO is due to substitution of key substrate binding residues in active site pocket. Additionally, a few
more substitutions similar to antizyme inhibitor (AZI), a non-functional homologue of ODCs, were identified in the active
site. Here, we establish the fact that EhODC sequence has conserved PLP binding residues; in contrast few substrate binding
residues are mutated similar to AZI. Further sequence analysis and structural studies revealed that EhODC may represent as
an evolutionary bridge between active decarboxylase and inactive AZI.
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Introduction
Entamoeba histolytica is responsible for causing amoebiasis,
amoebic liver abscess and amoebic colitis in humans. It is the
third major and a dangerous public health problem in the world
[1,2]. Though a small number of drugs including metronidazole,
emetine, tinidazole, chloroquine and nitrazoxanide are used for
the treatment of the disease, most of them are associated with
numerous side effects. In some cases, frequent use of these drugs
has led to the development of clinical drug resistance in the
pathogen [3,4]. Thus, it is crucial to identify and elucidate a potent
metabolic pathway in E. histolytica which could be set as a
therapeutic target for development of new anti-amoebic drugs.
In last few decades, the polyamine metabolic pathway in
protozoan diseases including African sleeping sickness [5],
giardiasis [6] and leishmaniasis [7] has emerged as a potential
therapeutic target [8]. The polyamines such as putrescine,
spermidine and spermine are essential polycationic compounds,
which are involved in various cellular processes that govern cell
growth and proliferation [9]. Subsequently, the actively prolifer-
ating cells have higher concentrations of polyamines. The
intracellular concentrations of polyamines are tightly regulated
by different mechanisms including biosynthesis, inter-conversion,
degradation, and uptake from the surrounding through polyamine
transporter. The failure in regulation of polyamine levels in cells
has been linked to various cancers. Hence, polyamine metabolic
pathway is also a potential target for cancer treatment [10,11,12].
Consequently, not only the polyamine biosynthetic pathway but
also the key components of polyamine homeostasis are potential
therapeutic targets [8]. The two enzymes of polyamine biosyn-
thesis pathway, ornithine decarboxylase (ODC) and S-adenosyl-
methionine decarboxylase (SAMDC) are highly-regulated and
have a very short half-life by which cells quickly alter the levels of
polyamines [13].
Ornithine decarboxylase catalyzes the first and rate-limiting
step of polyamine biosynthetic pathway. L-ornithine is decarbox-
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ylated by ODC enzyme in the presence of cofactor pyridoxal-59-
phosphate (PLP) to produce putrescine. The enzymatic activity of
ODC is tightly regulated by a distinct mechanism in which
polyamines induce the expression of a regulatory protein called
antizyme (AZ) by +1 ribosomal frameshifting [14]. AZ inhibits
ODC enzyme activity by binding and disrupting active ODC
homodimers, and subsequently marks the enzyme for ubiquitin-
independent degradation by the 26S proteasome [15,16]. Addi-
tionally, AZ negatively regulates the uptake of polyamines by
repressing polyamine transporter [17]. Thus, polyamine homeo-
stasis is maintained in a cell through polyamines themselves via a
negative feedback system, by governing the synthesis of AZ
protein.
Furthermore, in mammals, the activity of antizyme is negatively
regulated by a protein called antizyme inhibitor (AZI). AZI binds
to antizyme and blocks the binding of antizyme to ODC which
down regulates ODC degradation as well as leads to ODC
activation. AZI has higher binding affinity for antizyme as
compared to ODC which results in antizyme sequestration and
elevation of ODC levels [18,19,20,21,22,23]. Previously, it has
been reported that AZI is homologous to ODC and the major
residues involved in catalytic activity of ODC are conserved in
AZI [24]. However, AZI does not possess enzymatic activity due
to changes in the sequence that lead to protein inability to bind
cofactor PLP along with the failure in decarboxylation activity
[24,25,26].
In E. histolytica, ODC is the only enzyme of polyamine
biosynthetic pathway that has been reported to exist in the
organism [27]. The analysis of polyamine content shows that
considerable amount of putrescine is present in E. histolytica. While,
very low levels of spermidine and no spermine is detected
supporting the absence of other genes of polyamine biosynthetic
pathway in E. histolytica genome [28,29]. Interestingly, the
comparison of EhODC kinetic parameters with other well
characterized ODCs indicates that it has low substrate affinity
and catalytic efficiency [29]. Moreover, DFMO, a suicide
substrate inhibitor of ODC is used for the treatment of African
sleeping sickness, a protozoan disease caused by Trypanosome brucei
gambiense [30,31]. Interestingly, DFMO being an effective drug
against T. brucei gambiense is reported to have relatively poor effect
on the more virulent strain T. brucei rhodesiense [32,33]. Further-
more, the ODC of E. histolytica, being a pathogenic strain from
protozoa kingdom, is insensitive to DFMO due to sequence
divergence in the substrate binding residues [29,34,35,36]. Natural
resistance to DFMO within the same Trypanosome species as well as
within the protozoa kingdom draws attention towards the
sequence and structural divergence for their evolutionary adap-
tation.
In this study, we have determined the crystal structure of
EhODC to elucidate the structural features responsible for DFMO
insensitivity and low substrate binding affinity. Furthermore,
detailed comparative sequence and structural analysis was
performed with functional ODCs and non-functional ODC
homologue i.e. AZI to investigate the evolutionary status of
EhODC.
Materials and Methods
Reagents
Restriction enzymes NdeI, XhoI, T4-DNA ligase and phusion
polymerase were purchased from NEB. Primers were ordered
from Integrated DNA Technology. HisTrap HP Ni Sepharose
column and Hiload 16/60 Superdex 200 pg size exclusion column
were obtained from GE healthcare. For crystallization, PEG ION
screens were obtained from Hampton Research (Hampton
Research Inc. Aliso Viejo, CA). The plasmid pET30a containing
full length of EhODC was taken as template for sub-cloning [29].
Cloning of C-terminal truncated EhODC
Polymerase Chain Reaction (PCR) amplification was carried
out using forward primer 59-ATATCCATATGAAACAAA-
CATCTCTAGAAG-39 and reverse primer 59- GAACCTC-
GAGTCATTCAATTGACTTAGGGATTTGAAT-39 with NdeI
and XhoI restriction enzyme sites respectively to obtain DNA
fragment encoding the C-terminal 15 residues truncated EhODC
(EhODCD15). The previously cloned full-length EhODC was used
as a template in the PCR reaction [29,36]. PCR was performed in
a 50 ml reaction mixture containing 10 ml of 56HF phusion buffer
supplied with the enzyme, 300 mM of dNTP mix, 6.25 pmol of
each of forward and reverse primers, 10 ng of template DNA, 1 ml
of 2.5 U/ml phusion polymerase and water. The reaction was
performed with initial denaturation at 95uC for 30 s, followed by
30 PCR cycles of denaturation at 95uC for 30 s, annealing at 51uC
for 60 s and extension at 72uC for 1 min and 15 s. A final
extension was carried out at 72uC for 15 min. The resultant PCR
product was subcloned into NdeI and XhoI sites of pET-28c with
His6-tag preceding the N-terminal and tobacco etch virus (TEV)
protease cleavage site to allow the removal of tag from
recombinant protein. Ligated product was transformed into
freshly prepared E. coli DH5a competent cells. Kanamycin
resistant transformants were selected and grown in LB broth
supplemented with 50 mg/ml kanamycin. The pET28-
EhODCD15 plasmid was isolated and right size insert in the
construct was confirmed by DNA sequencing from TCGA, New
Delhi.
Expression and purification
The pET28-EhODCD15 plasmid containing truncated EhODC
gene was transformed into E. coli BL21 (DE3) competent cells. For
protein expression, transformed BL21 (DE3) cells were grown at
37uC to an optical density of ,0.6 at 600 nm (OD600) and
induced with 0.5 mM isopropyl-ß-thiogalactopyranoside (IPTG).
Induced cultures were transferred to 18uC and cells were grown
for ,14 h. Cells were harvested by centrifugation at 5,000 rpm at
4uC and cell pellets were stored at 220uC until further use. For
protein purification, cell pellets from 1 litre culture were re-
suspended in 20 ml of ice cold binding buffer containing 50 mM
Tris HCl (pH 7.5), 40 mM imidazole, 250 mM sodium chloride,
2 mM phenylmethylsuphonyl fluoride (PMSF) and 5% glycerol
(v/v). Lysozyme was added to a final concentration of 100 mg/ml
and kept on rocking platform at 4uC for 45 min. Cells were
disrupted by sonication on ice with 50% amplitude and a pulse of
20 sec on and 60 sec off for 15 min. The lysate was centrifuged at
18,000 rpm for 45 min at 4uC to separate supernatant from cell
debris. The supernatant was loaded onto 5 ml HisTrap HP affinity
column pre-equilibrated with the binding buffer. Protein was
eluted by running a linear gradient of 40–1000 mM imidazole in
60 ml of buffer A [50 mM Tris HCl (pH 7.5), 1 M imidazole,
250 mM sodium chloride and 5% glycerol (v/v)] at a flow rate of
1 ml/min. Eluted fractions were analyzed on sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and frac-
tions containing pure protein were pooled together. To remove the
N-terminal His-tag, TEV protease was added to the sample with
protein to TEV ratio 1:20 and incubated for ,12 h at 4uC and
simultaneously dialyzed against buffer A without imidazole. To
remove uncleaved His-tag protein and His-tag TEV protease, the
sample was again loaded onto 5 ml HisTrap HP column. Flow-
through containing EhODCD15 without His-tag was collected and
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concentrated using a 10 kDa cut-off Amicon Ultra-15 concentra-
tor (Millipore, Bedford, Massachusetts, USA). The concentrated
protein was loaded onto HiLoad 16/60 prep grade Superdex 200
size-exclusion chromatography column pre-equilibrated with
buffer B containing 30 mM HEPES-Na (pH 7.5), 250 mM NaCl,
1 mM EDTA, 10% (v/v) glycerol and 1 mM DTT. The major
peak fractions containing pure protein were pooled and concen-
trated to 5 mg/ml. Homogeneity of purified EhODCD15 protein
was analysed on 12% SDS-PAGE. Protein concentration and yield
were determined using the Bio-Rad protein assay kit with bovine
serum albumin (BSA) as a standard.
EhODCD15 enzymatic activity
To confirm that the truncation of 15 residues from C-terminus
does not inactivate EhODC, ornithine decarboxylation activity of
purified protein and production of putrescine was spectrophoto-
metrically determined using the method developed by Badolo et al
[37]. Enzymatic activity of the purified EhODCD15 protein was
compared with full-length EhODC [36].
Gel filtration analysis
The average molecular weight of EhODCD15 was determined
using size exclusion chromatography and compared with previ-
ously characterized full-length EhODC [36]. In brief, the purified
protein was concentrated to 5 mg/ml and was injected onto
HiLoad 16/60 Superdex 200 gel filtration chromatography
column using A¨KTA purification system (GE Healthcare). Protein
was allowed to pass through the column at a rate of 0.5 ml/min.
For the molecular weight estimation of EhODCD15, the elution
profile of the major peak containing purified protein was
compared with the elution profile of the standard Gel Filtration
HMW Calibration kit molecular weight markers (GE healthcare).
Crystallization
For crystallization, purified EhODCD15 protein was concen-
trated to 12.5 mg/ml in 30 mM HEPES-NaOH buffer (pH 7.5)
containing 1 mM EDTA, 0.25 M NaCl, 1 mM DTT and 10%
(v/v) glycerol. Crystallization trials were performed using the
sitting drop vapour diffusion method in 96 well plates (Hampton
Research) at 20uC and 4uC. The drops were prepared by mixing
2 ml of protein solution with 1 ml of reservoir solution and
equilibrated against 80 ml reservoir solution. Hampton Research
crystallization screens Crystal screen, Crystal screen 2 and PEG/
ION screen (Hampton Research, USA) were used to explore the
initial crystallization conditions. Crystals were obtained in PEG
ION screen containing 20% PEG 3350 in 0.2 M LiCl solution
maintained at pH 6.8. Diamond shaped crystals of EhODCD15
appeared in four months at 20uC. Prior to data collection, crystal
was cryo-protected by bathing it in mother liquor containing 3%
(v/v) ethylene glycol for 10 s. The crystal was flash-frozen under
cryogenic conditions at 100 K using liquid nitrogen stream to
prevent radiation damage during data collection.
Data Collection and structure determination
The diffraction data of EhODCD15 were collected at 100 K
using Cu Ka radiation generated by a Bruker Microstar-H
rotating-anode generator assembled with MAR 345 imaging-plate
system. The data were collected at 1.54 A˚ with a crystal-to-
detector distance of 200 mm and 1u oscillation per image with
20 min exposure per frame. Crystal diffracted to 2.8 A˚ resolution.
The data were indexed, integrated and scaled using HKL2000
program [38]. Table 1 summarizes data collection and processing
statistics. The structure was solved by molecular replacement
method using Molrep program of CCP4-6.0 suite [39]. The model
was generated using previously reported crystal structure of
human ODC (PDB ID: 2ON3) [40]. Non-crystallographic
symmetry restraints were applied throughout the refinement
stages using four EhODCD15 molecules in the asymmetric unit.
Structure refinement was performed using CNS v.1.2, Phenix v
1.7.2-869, and REFMAC 5.2 refinement tools [41,42,43]. Rounds
of model building were carried out using program Coot v 0.6.2
[44]. The quality of the model was evaluated by PROCHECK
[45].
Sequence Analysis of EhODC
The sequence of EhODC, along with other functional ODCs
and AZI were retrieved from NCBI database [46]. Multiple
sequence alignment and phylogenetic tree of these sequences were
obtained using ClustalW [47] for evolutionary variation analysis.
Model generation for active site analysis
In the crystal structure of EhODCD15, the flexible loops missing
in one subunit were present in the other subunits. Therefore,
coordinates for missing loops near active site in the structure were
Table 1. Statistical representation of data collection and
structure refinement parameters along with quality of the
model accessed by Ramachandran plot.
Data collection
Space group P212121
Unit cell parameters
a (A˚), b (A˚), c (A˚) 76.66, 119.28, 179.28
Resolution (A˚) 99.5–2.87 (2.92–2.87)a
Number of reflections 35570
Completeness (%) 92.1(59.0)a
Mean redundancy 3.4 (2.1)a
I/s 4.82 (2.0)a
Rmerge
b (%) 0.150 (0.670)a
Refinement
Resolution (A˚) 99.5–2.87 (2.92–2.87)a
Number of non-H atoms in asymmetric unit
Protein 10484
Water molecules 101
R-factor (%) 25.3
Rfree
c value (%) 29.9
Average B-factor (A˚2) 54.4
Rms deviations
bond lengths (A˚) 0.005
bond angles (u) 0.831
Ramachandran plot
Residues in favored region (%) 88.7
Residues in allowed region (%) 10
Residues in generously allowed region (%) 0.9
Residues in outlier region (%) 0.4
avalue in parentheses are for the highest resolution shell.
bRmerge =S | I2I¯ |/S I | where I = observed intensity and I¯ = average intensity.
cRfree =S (|F|obs2|F|calc|)/S |F|obs where |F|obs are observed structure factor
amplitudes for a given reflection and |F|calc are calculated structure factor
amplitude.
doi:10.1371/journal.pone.0053397.t001
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generated by MODELLER 9.10 [48] using the solved crystal
structure of one subunit of EhODC as a template. Evaluation of
the steriochemical properties of obtained structure having built-in
loops was performed using PROCHECK [45]. All the figures of
structure and active sites were generated using PyMol [49].
Results and Discussion
C-terminal Truncation and Purification of EhODC
The ODC enzyme from E. histolytica belongs to fold type III
group IV decarboxylase of a B6-dependent family, having
eukaryotic ornithine decarboxylase characteristics [50,51]. Under
this classification, crystal structures are only available from three
different sources including human, mouse and Trypanosome brucei
ODC [52,53,54]. For crystal structure determination of EhODC,
full-length protein was purified using the previously established
protocol [36] and was used for crystallization experiments.
However, extensive crystallization trials of full-length EhODC
were unsuccessful. In order to decrease the conformational
heterogeneity, it is a common practice to truncate the flexible N
and/or C-terminal residues to facilitate the crystallization process.
Therefore, EhODC sequence was examined to identify disordered
regions using bioinformatics tools DisEMBL and GlobPlot
[55,56]. These programs predicted a fragment of approximately
13–17 residues at the C-terminus of EhODC to be flexible.
Additionally, it has been reported that the truncation of 37
residues from the C-terminus of mouse ODC resulted in protein
stability and has been crystallized successfully for structure
determination [53,57,58]. The C-terminal sequence of EhODC
shows similarity with mouse ODC in having a PEST like sequence
[36]. Based on these observations, 15 residues were deleted from
the C-terminus of EhODC. Expression and solubility of
EhODCD15 construct was optimized by varying induction
temperature (37uC, 25uC, and 18uC). Maximum solubility was
observed at 18uC when induced with 0.5 mM IPTG for ,14 h.
Recombinant EhODCD15 was purified in three sequential
purification steps, with yield of ,5 mg per liter of E. coli culture.
Elution profiles from the gel filtration column demonstrated that
EhODCD15 exists in the dimeric form similar to full-length
EhODC [36]. The purified protein exhibited a single band of
approximately ,45 kDa in 12% SDS-PAGE gel (Figure 1). The
enzymatic activities of EhODCD15 and wild-type proteins were
compared using previously established protocol [36]. The
comparative analysis of both the full-length and EhODCD15
forms didn’t show any notable difference in the activity indicating
that the truncation of 15 residues from the C-terminus of EhODC
does not affect its activity.
Crystal packing
Crystallization of purified EhODCD15 was performed using
sitting drop vapor diffusion method. Crystals were obtained at
20uC in Hampton PEG ion screen 4 containing 20% (v/v) PEG
3350, 0.2 M LiCl maintained at pH 6.8. Crystals belonged to the
orthorhombic space group exhibiting P212121 symmetry with unit
cell parameters a= 76.66, b= 119.28, c= 179.28 A˚ and
a= b= c= 90u. The crystal diffracted to 2.8 A˚ resolution, possess-
ing four molecules per asymmetric unit and the solvent content
was calculated to be 46.69% with a Matthews coefficient of
2.2 A˚3 Da21. Quality of the obtained structure was assessed with
the PROCHECK program showing 88.7% of the residues in the
favored region, whereas 10% in allowed, 0.9% in generously
allowed and only 0.4% residues are observed in the disallowed
region of Ramachandran Plot (Table 1).
The four monomers in the asymmetric unit of crystal are
arranged as two separate dimers (subunits A, B and subunits C, D)
facing each other at the convex surfaces. Each monomer in a
dimer makes side to side contacts with each other forming an
overall bent structure. Further, as the loops in a dimer interface
are disordered and clear density was not observed, the central part
of dimer forms a hollow structure. In the dimer, chain A and chain
B are arranged in head to tail manner at origin (0,0,0) of
orthorhombic unit cell (Figure 2). The b/a barrel of chain A and b
sheet of chain B pose at origin and their counterpart extends along
X-direction. Dimer of AB is situated along with X-axis by an angle
of 30u approximately; whereas other dimer CD is situated at
rotation angle of 180u with a screw distance of 19.1 A˚ that
occupies approximately one quarter of unit cell. The crystallized
structure of EhODCD15 consists of a tetramer. The asymmetric
unit contains two dimers comprising of chain A, B, C, D. The total
area of the molecule of EhODC containing four molecules was
estimated to be 61227.6 A˚2. Each dimer interacts with its
symmetry mate to form dimer-dimer interfaces as A–B dimer
interacts with C–D dimer (Figure 2). Interface area evaluated by
PISA web server was averaged to 1373.4 A˚2 which was 1599.8 A˚2
and 1147.0 A˚2 between B, A and D, C respectively [59].
In the tetrameric structure, residues Phe91 and Leu87 of chain
A interact with Ser388 of chain C through a water molecule. In
addition, Glu90 of chain A interacts to Ser388 of chain C through
polar interaction. Similarly, Asp88 of chain A is forming direct
interaction with residue Leu386 of chain C and vice versa. Residues
Glu110 and His113 of chain B are at a distance of 3.1 A˚ and 3.3 A˚
from Lys84 and Asp88 of chain D showing polar interactions and
vice versa (Figure 3).
Overall structure and folding
Each monomer consists of b/a barrel and b-sheet domain
which are arranged identical to previously known ODC structures
(Figure 4). However, the tetramer arrangement displays a number
of unusual features. Residues from barrel involved in contact and
dimer formation are located at the surface or in proximity to sheet
domain of opposite monomer. Interface residues of helices a5, a7,
a8 and a9 of chain A barrel form extensive contacts with sheet
domain S2 of chain B. All four chains in asymmetric unit showed
similar structures and are involved in similar interactions. The
analysis of dimer-dimer interactions exhibited large intermolecular
distances of ,4.0 A˚. In a monomer, helix a1 is connected to sheet
b1 (Gly27-Phe31) through a loop and enters the barrel. The barrel
is composed of eight helices i.e. a2 (T33-N46), a3 (P62-L71), a4
(L80-L89), a5 (Y105-L114), a6 (I124-Y133), a7 (D163-K175), a8
(E194-F213) and a9 (F232-L246) followed by eight alternate b-
strands b2 (R51-A55), b3 (G74-C77), b4 (I96-Y98), b5 (H118-
V121), b6 (G138-R142), b7 (V182-F184), b8 (L219-D221) and b9
(R253-A256). The sheet domain comprises of eight randomly
arranged b-strands which can be further divided into S1 and S2 b-
sheets that are perpendicular to each other. Sheet S1 consisted of
four sheets b10 (F267-S271), b15 (L355-F357), b16 (I381-T383) in
addition to b1, which are roughly perpendicular to S2 containing
b11 (H274-Q281), b12 (K284-S291), b13 (Y325-Y330) and b14
(A341-L345) (Figure 4). However, both domains are connected by
two loops in between b1-a2 and a10-b10. The barrel and b-sheet
domains of the monomeric subunits are associated in head to tail
manner in the dimer. In addition, various polar interactions at the
dimer interface including salt bridges and hydrophobic interac-
tions are involved in the formation of dimer. The structure of
EhODC has several highly mobile loop moieties that are depicted
by dashed lines in Figure 4.
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Figure 1. Purification and gel filtration profile of EhODCD15. A) 12% SDS-PAGE gel showing the affinity purified protein Lane 1: Molecular
weight markers shown in kDa. Lane 2–3: Protein purified by affinity chromatography. B) Elution profile of the EhODC1D15 protein. The protein was
eluted at a volume of 74 ml corresponding to molecule weight of ,87 kDa. Insert shows the purified protein in 12% SDS-PAGE after gel filtration
chromatography.
doi:10.1371/journal.pone.0053397.g001
Figure 2. Schematic representation of overall structure of the model obtained after molecular replacement. A) Cartoon diagram of
tetrameric model of EhODC showing AB-CD, dimer-dimer interface; B) Active site of EhODC at the interface of dimer where (9) denotes the residues
from the other subunit.
doi:10.1371/journal.pone.0053397.g002
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Comparative analysis of active site architecture
The ODC enzyme is an obligate homodimer with two
symmetry-related active sites located at the dimer interface.
According to our previous report, EhODC enzyme is functionally
active in the dimeric form [36]. As expected, the crystal structure
of EhODC contains two equivalent active site pockets at the dimer
interface formed by residues that are contributed from both the
subunits (Figure 2). The proper orientation of active site formed by
two subunits is highly essential for functionality of the enzyme.
The active site in EhODC is mainly contributed by loops from
both the subunits. For comparative analysis of active site, we
superimposed the EhODC structure over TbODC complexed with
DFMO. The super-imposition of monomers shows root mean
square deviation (rmsd) of 1.18 A˚ whereas super-imposition of
dimer shows rmsd of 1.7 A˚. Active site superimposition of TbODC
and EhODC shows that most of the conserved residues in active
site of EhODC share same positions as in TbODC, however few
residues pose in different orientation (Figure 5). His185, Gly259,
Arg260 and Tyr363, the well conserved PLP binding residues of
EhODC share the position and have orientation similar to the PLP
Figure 3. Tetrameric structure with dimer-dimer interaction. A–C) shows the interaction between chain A and chain C. B–D) indicates the
interaction between chain B and chain D. Pink dashes shows the interaction of residues through water molecule and green dashes indicates the polar
interactions. Symbol (0) and (9) denotes the residues of chain C and chain D, respectively.
doi:10.1371/journal.pone.0053397.g003
Figure 4. Crystal structure of EhODC monomeric subunit. A) Cartoon diagram of the monomer showing arrangement of barrel and sheet
domain. B) Topology diagram of monomer of EhODC where helices are represented with cylinder and sheets with the arrows connected with loops,
dashed line indicates the sequence missing in the structure.
doi:10.1371/journal.pone.0053397.g004
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binding residues (His197, Gly276, Arg277 and Tyr389 respec-
tively) of TbODC (54, PDB ID: 2TOD). The side chains of these
conserved residues interacting with PLP through polar interactions
in TbODC are also expected to bind PLP and correctly orientation
it into the active site of EhODC. Interestingly, Ser200 of TbODC
is present in a loop and is seen interacting with PLP in TbODC
structure (54, PDB ID: 2TOD). However, this residue (Ser188) is
also conserved in EhODC, but shows small displacement from its
expected position and has opposite orientation in the crystal
structure of EhODC. Though, at this point it cannot be ruled out
that the flexible loop of EhODC possessing Ser188 may approach
the active site and may orient Ser188 in favourable position in the
presence of PLP, whereas apo-enzyme might not restrict its
position. Addition to this, Gly225 of EhODC shares exact position
of Gly237 of TbODC, whose backbone carbon chain contributes
to polar interactions. Apart from this, few residues interact with
PLP through water molecules which include residues Phe238,
Tyr278, Arg154 and Ala111 in TbODC. These residues are
present at the same position in EhODC active site except Ala111
where it is substituted by Ser99 in EhODC. Overall, the
architecture of EhODC for binding to PLP is similar to that of
TbODC.
DFMO, a substrate analogue makes a stable covalent bond with
conserved Cys residue in the active site of ODC enzyme and
inhibits its catalytic reaction. Binding of DFMO in the proper
orientation for covalent bond formation with its active site is also
supported by its interaction with other residues that are there in
the substrate binding pocket. To extricate the intricate structural
details of EhODC responsible for low substrate affinity and/or
DMFO insensitivity, structural comparison of EhODC active site
architecture for substrate/DFMO binding was done with the
active site of DFMO bound TbODC crystal structure (Figure 5)
(54, PDB ID: 2TOD). In TbODC, Cys’360 from counterpart
subunit plays the most critical role in DFMO binding by making a
permanent covalent bond with the enzyme. However, covalent
bond formation of Cys’360 with substrate L-ornithine has not
been reported for any ODC enzyme. In addition to this, the next
residue of TbODC Asp’361 helps to position the Cys’360 residue
in proper orientation and also interacts with DFMO through a
water molecule. In contrast, Cys’334 the conserved residue of
EhODC that is expected to form a covalent bond with DFMO is
slightly displaced from its position and has distinct orientation that
is structurally unfavourable for covalent linkage with DFMO. In
addition, the residue Asp’361 of TbODC is substituted by Asn’335
in EhODC, which is not expected to interact with DFMO.
Furthermore, alpha-carbon backbone consisting residues Tyr331
and Asp332 in TbODC shows direct interactions with bound
DFMO and these interactions play a role in proper DFMO
molecule orientation in the active site pocket. However, these
residues are mutated to Phe305 and Glu306 respectively in
EhODC. Also, EhODC crystal structure reveals that the loop
consisting of Phe305 and Glu306 residues is not located close to
the active site thus may not contribute to DFMO binding.
Moreover, residue Tyr’323 from other subunit of TbODC also
supports the favourable orientation of DFMO by side chain
hydroxyl group interaction with DFMO through a water
molecule. Tyr’323 is replaced with His’296 in EhODC and the
loop containing His’296 residue is positioned away from the active
site (Figure 5). In contrast, the cofactor PLP and substrate L-
ornithine are accommodated in EhODC active site with polar
interactions to facilitate the catalysis (Figure 2) [29,35]. These
structural details indicate that amino acid substitutions in the
active site of EhODC create a novel architecture which not only
makes it resistant to DFMO but also lowers its catalytic efficiency
by weakening substrate binding, as the reported Km values for L-
ornithine for active but DFMO sensitive T. brucei and mouse ODC
Figure 5. Superimposition of active site of EhODC with TbODC bound to DFMO. Residues of active site at the dimer interface are
represented in sticks. TbODC residues are colored with green, EhODC residues are colored with orange. PLP and DFMO are colored with blue and
polar interactions were indicated by black dashes; water molecule in shown in red sphere. Residues with (9) symbol are of opposite monomer.
doi:10.1371/journal.pone.0053397.g005
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enzymes are 0.24 mM and 0.09 mM respectively, whereas for
DFMO resistant EhODC it is 1.5 mM [29,60]. Not only
substituted residues, but also the displacement of loops (His’296
loop/Phe305 and Glu306 loop) away from EhODC active site
seems to contribute towards DFMO insensitivity.
EhODC sequence and structural comparison with ODC
homologs
The novel active site architecture revealed from the crystal
structure of EhODC and previously reported low catalytic
efficiency of the enzyme hints towards possible adaptive evolution
which lead to DFMO insensitive. AZI is an inactive ODC
homolog that possesses a broader active site due to unusual
packing of AZI dimers [61]. The architecture of AZI active site
does not favour the accommodation of substrate as well as the co-
factor for enzyme catalysis, which makes it an inactive homolog of
ODC. Recently, it has been proposed that several homologs of
ODCs including putative antizyme inhibitors apparently arise
independently through evolution [46]. Robust sequence analysis
and active site structure comparisons were performed to explore
the evolutionary relationship of EhODC with respect to ODC
homologs including AZI and to uncover the possibility of
additional EhODC functions. Multiple sequence alignment was
done and phylogenetic tree was generated for ODC homologues
including functional ODC and nonfunctional AZI (Figure 6).
AZI is an inactive homolog of ODC which has lost decarbox-
ylation activity due to mutation of critical residues in the active site
[24,25,26,46,62]. However, they are important in mammals as
they are responsible for antizyme down regulations, thus regulate
the ODC activity in cell system [21]. In this study, we have
identified 27 residues from sequence alignment of ODCs from
different organisms responsible for the formation of active site
pocket and in ODC enzyme dimerization (Figure 7). Out of 27
residues, 16 residues contribute to the active site formation by
interacting with cofactor PLP, 5 residues for substrate binding, 3
residues for salt bridge formation, 3 residues as critical interface
residues and 1 residue for dimerization (Figure 7).
From various mutational studies, it is reported that a conserved
Lys (Lys57 in EhODC) is important as it forms Schiff base with
PLP which is later displaced by L-ornithine that undergoes
decarboxylation through nucleophilic attack via a conserved Cys
(Cys3349 in EhODC) [36,63,64,65]. However, both the residues
are well conserved in both functional ODCs and AZI (except in
few AZIs). In all functional ODCs including ODCs from T. brucei,
Homo sapiens (HsODC) and mouse, residue Ala111 and Arg154
(HsODC) are highly conserved and interact with PLP through
water. Interestingly, in EhODC, though Arg142 is conserved,
however Ala111 is uniquely substituted with Ser99. AZI possesses
substitution at both the positions with Ala to Thr/Ile/Ser and Arg
to His/Gln that make AZI incapable of binding to PLP. Out of
sixteen PLP binding residues, AZIs have major mutations in five
positions whereas EhODC possesses a single mutation at position
99 with substitution of Ala to Ser (Figure 7 and Figure 8).
In HsODC, five residues Tyr323, Tyr331, Asp332, Cys360 and
Asp361 are reported to be key active site residues which interact
with L-ornithine and these residues are highly conserved in all
functional ODCs (Figure 7). However, EhODC is an exception
where only Cys334 is conserved while both Tyr and both Asp
residues are substituted by His296, Phe305, Glu306 and Asn335
respectively. The substitution of active site residues at His296 and
Figure 6. Multiple sequence alignment of ornithine decarboxylase and its homologues antizyme inhibitor to determine the
conservation of sequence and mutation of active site and substrate binding residues. Circles indicate the residues important for
enzymatic activity. Numbering is according to EhODC.
doi:10.1371/journal.pone.0053397.g006
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Asn335 positions are unique to EhODC as these two residues are
found to be conserved as Tyr323 and Asp361 in both AZI as well
as in functional ODC. Interestingly, substitution at Glu306 instead
of Asp332 is similar to AZIs, the inactive homologs of ODCs.
However, in AZIs only Asp332 is substituted by Glu, whereas
other four residues are mostly conserved (Figure 7).
Furthermore, in case of TbODC and other functional ODCs,
Tyr331 contributes to form an aromatic zipper responsible for
complementary packing in two monomers [53,54]. In AZI, this is
mutated to Ser rendering a loose contact between monomers [61].
But in EhODC, same residue is substituted by aromatic amino
acid Phe305 that is expected to perform same job in aromatic
zipper. The mutation of Tyr to Phe is also reported in Plasmodium
falciparum, Leishmania donovani and Glycine max ODCs (Figure 7,
Figure 7) [46,66].
AZI genes have accumulated mutations in key residues that are
important for ODC activity. In Petromyzon marinus, the homologue
of AZI as classified on the basis of conserved key amino acid
residues was found to be a functional ODC [67]. In contrast to
this, ODC from Aedes aegypti is found to be enzymatically non-
functional [46]. Thus, mutations in and around active site, ranging
from substitution of one residue to substitution of fourteen residues
in single polypeptide may cause enzyme inactivation. In T.
nigroviridis, 11 residues are altered in the active site whereas in
mammals 4 residues are altered to convert a functional ODC to a
nonfunctional homolog [46]. However, in Drosophila melanogaster,
though all 18 key residues of active site are conserved, but a single
mutation of Asp332Tyr hinders dimer formation in ODC in
addition to cofactor and substrate binding, which makes it a
nonfunctional ODC.
The evolutionary relationship of ODC and AZI can be
evaluated by considering the root of phylogenic tree which
connects the branch of both homologs. Evidences indicated that
both the homologs are from same subfamily and have evolved and
Figure 7. Sequence analysis of ODC and antizyme inhibitor, comparing the active site residues of ODC/AZI from various organisms.
Abbreviation denoted: Cf for cofactor binding; Bs salt bridge formation; S substrate binding residues; If dimer interface residues; Di important for
dimer formation. Species with the name of protein are shown on left side. Colour indication: Violet columns signifies the mutation in AZI; Orange
columns signifies the mutated residues in E. histolytica ODC which are similar to AZI; Gray shows the unique mutations in EhODC which is neither
conserved in ODC nor in AZI; Blue indicate the mutation in EhODC which are rarely found in AZI and functional ODC; Olive color point out the
mutations in EhODC which are similar to some ODC. Sequence analysis and numbering has been done according to EhODC. Residues which are not
conserved are shown by single letter, the conserved residues are indicted by – and D indicates the deleted amino acids. % identity indicates the
identity of EhODC sequence with other homologous ODC sequences [46].
doi:10.1371/journal.pone.0053397.g007
Crystal Structure of ODC from E. histolytica
PLOS ONE | www.plosone.org 9 January 2013 | Volume 8 | Issue 1 | e53397
diverged according to their function. In phylogenetic tree, the
group of AZI and ODC make different clusters according to the
sequence alignment. Interestingly, EhODC is clustering to the
ODC group just beneath the Aedes aegypti which is a nonfunctional
ODC due to His197Asn and Asp332Arg substitutions as shown in
Figure 7 and Figure 9. ODC of Aedes aezypti, being a non-
functional ODC, represents the border line of functional ODCs
and nonfunctional AZI. EhODC, the enzyme with low catalytic
efficiency is found to be more evolutionarily related to nonfunc-
tional ODC of Aedes aezypti and AZIs. These evidences from
sequence alignment and phylogeny profile of EhODC allow us to
establish the fact that during the course of evolution it gained
DFMO resistance by acquiring critical alternation in its sequence
similar to both functional ODCs and non-functional AZI.
Though, the evolutionary changes in the sequence also influenced
its catalytic efficiency. However, the possibility of additional
biological role of EhODC such as antizyme inhibitory activity
needs to be investigated.
Conclusion
In the present report, we successfully determined the 3D
structure of EhODC to elucidate its intricate active site architec-
ture that made it DFMO insensitive. Further on the basis of
sequence analysis, we unveiled many unique characteristics of
EhODC that show similarity with both functional ODC and non-
functional AZI. EhODC exists as a dimer like other functional
ODCs and in contrast AZI is monomer in solution due to weaker
interaction between two monomers. Interface of EhODC shows 45
contacts and 16 hydrogen bonds in addition to salt bridges which
stabilize the dimer. As studied in AZI structure (mouse AZI), only
43 contacts and 15 hydrogen bonds are reported which lack salt
bridge formation and make interface less interactive as compared
to ODC [61]. Structure of EhODC at 2.8 A˚ revealed two salt
bridges between Lys157-Asp238 at a distance 2.9 A˚ and Asp122-
Arg277 at 3.2 A˚. Same salt bridges are also reported in HsODC
that contributes to dimerization. Though, same residues i.e.
Lys169, Asp364, Asp134, and Lys294 are conserved in AZI
(mouse), still residues do not approach to form the salt bridge [61].
Furthermore, AZI is inefficient to bind to PLP consequently
unable to carry out decarboxylation reaction. The structure of AZI
(mouse) reveals that the active site is too wide to make suitable
pocket for substrate and PLP binding. However, EhODC binds to
PLP and catalyzes decarboxylation of L-ornithine and relatively
less active as compared to other active ODCs. It is interesting to
note that though EhODC possesses similar property with other
ODC on the basis of structure and function, it shares some
similarity with AZI based on amino acid sequence. Firstly, the
substrate binding residue Asp332 (HsODC) is conserved in
functional ODCs where in EhODC same residue is altered to
Glu306 and Glu is well conserved in AZI. Secondly, PLP binding
residue Ala is altered to Ser in EhODC and such alternation is
reported in AZI of Danio rerio, Tetraodon nigroviridis and Anolis
crolinensis. Thirdly, EhODC possesses unique mutations at His296
and Asn335 those are neither reported in any functional ODC or
AZI. Such alternation of critical residues particularly in protozoa
provides the evidences of adaptive evolution of ODC. AZI
dependent ODC regulation is only reported in higher organisms
and absent from lower organisms. Even such regulation is not
reported in protozoa till date. However, it can be hypothesized
that ODC in protozoa takes the modification towards AZI though
it functions less efficently as an active ODC and its function as AZI
needs to be investigated.
Our study will facilitate to investigate the molecular evolution of
ODCs and AZI. It also suggests additional functional properties
for EhODC such as it may also play a role similar to that of AZI in
E. histolytica. Additionally, availability of EhODC crystal structure
will be helpful in development of structure based anti-amoebiasis
drugs.
Figure 8. Active sites comparison of functional ODC, antizyme inhibitor and EhODC. A) Human ODC active site residues colored in blue. B)
EhODC active site residues identical to human ODC colored blue, residues identical to AZI colored green and unique to EhODC colored red. C) AZI
interface region showing residues identical to human ODC in blue and those are mutated colored green.
doi:10.1371/journal.pone.0053397.g008
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Accession number
Structure factors and final refined atomic coordinates for
EhODC have been deposited in the Protein Data Bank (http://
www.rcsb.org) with accession number 4AIB.
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